Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: Efficiency, safety and cost

Annals of Thoracic Surgery

Volumn 71, Issue 3, 2001, Pages 838-843

  Ray, Michael J ^a   O'Brien, Mark F ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; D DIMER; ENOLASE; PROTEIN S 100; TROPONIN I;

ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; APROTININ; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; COSTS AND COST ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SERINE PROTEINASE INHIBITORS;

EID: 0035098728     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)02229-3     Document Type: Article

References (21)

1. Relationship of platelet aggregation to bleeding after cardiopulmonary bypass
2. A practical guide to hemostatic management of post-open heart patients
3. Limiting excessive postoperative blood transfusion after cardiac procedures. A review
4. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass
5. Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery? A meta-analysis
6. High-dose epsilonaminocaproic acid versus aprotinin. Antifibrinolytic efficacy in first-time coronary operations
7. Comparison of the effects of epsilonaminocaproic acid and aprotinin on intra- and postoperative bleeding in heart surgery
8. Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs
9. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: Aprotinin vs tranexamic acid vs epsilon aminocaproic acid
10. Costbenefit, and efficacy of aprotinin compared with epsilonaminocaproic acid in patients having repeated cardiac operations. A randomized, blinded clinical trial
11. Economic evaluation of high-dose and low-dose aprotinin therapy during cardiopulmonary bypass
12. Epsilonaminocaproic acid plasma levels during cardiopulmonary bypass
13. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin
14. Antigenicity of protamine and aprotinin in cardiac surgery
15. Aprotinin versus lysine analogues: The debate continues
16. A brief review of studies evaluating the adverse effects of aprotinin therapy in aortocoronary bypass surgery
17. Analyses of coronary graft patency after aprotinin use: Results from the International Multicenter Aprotinin Graft Patency Experience (IM-AGE) trial
18. Release kinetics of serum cardiac troponin I in ischemic myocardial injury
19. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage
20. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin
21. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin